A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Latest Information Update: 23 Oct 2024
At a glance
- Drugs Dapagliflozin/pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boryung Pharmaceutical
Most Recent Events
- 23 Oct 2024 New trial record